What the FDA labels say about taking them together
Oliceridine and pregabalin
Oliceridine's FDA label of December 31, 2025 names pregabalin in its drug interactions section; the pregabalin labels PlainMeds reads (3) do not name oliceridine. The oliceridine label: “Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of hypotension, respiratory depression, profound sedation, coma, and death.”
Check it at the source: the oliceridine FDA label on DailyMed (effective December 31, 2025, Trevena, Inc.); the pregabalin FDA label on DailyMed (effective April 15, 2025, Viatris Specialty LLC).
What does the oliceridine label say about pregabalin?
Oliceridine label, drug interactionsBenzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of hypotension, respiratory depression, profound sedation, coma, and death. … anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol
Oliceridine label, warnings and precautionsRisks from Concomitant Use with Benzodiazepines or Other CNS Depressants Profound sedation, respiratory depression, coma, and death may result from the concomitant use of OLINVYK with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin or pregabalin], and other opioids, or alcohol).
Source: FDA drug label (OLINVYK), Trevena, Inc., effective December 31, 2025 (SPL set ce167984-8b9d-40b7-84ce-d0f33fff1eaa), via openFDA; the full label on DailyMed
What does the pregabalin label say about oliceridine?
Pregabalin's label (effective April 15, 2025) and its 2 other brand-application labels do not name oliceridine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Lyrica), NDA021446 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2025 (SPL set d4734e7d-5079-455e-8ff5-8f4539c998a9), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Oliceridine | Pregabalin | |
|---|---|---|
| Labeled for | Pain | Nerve pain and fibromyalgia, Seizures and epilepsy |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.0571 per capsule 100 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once